k141_31672_4	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	43.8	224	230	231	2.07e-60	188
k141_31672_4	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	43.6	227	230	232	2.77e-58	183
k141_31672_4	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	43.6	227	230	232	2.77e-58	183
k141_31672_4	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	43.6	225	230	233	1.62e-57	181
k141_31672_4	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	40.4	225	230	229	9.27e-56	176
k141_31672_4	CARD|gb|ATC67679.1|ARO:3000838|arlR	42.4	229	230	219	1.37e-55	176
k141_31672_4	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	43.0	228	230	239	1.77e-55	176
k141_31672_4	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.7	225	230	232	5.75e-55	174
k141_31672_4	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	40.3	226	230	231	2.24e-54	173
k141_31672_4	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.3	226	230	231	2.24e-54	173
k141_125659_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	41.1	219	225	219	1.79e-46	152
k141_125659_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.3	234	225	232	2.90e-45	149
k141_125659_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.2	232	225	232	8.18e-45	148
k141_125659_2	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	39.3	229	225	231	2.24e-44	147
k141_125659_2	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.3	229	225	231	2.24e-44	147
k141_125659_2	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.4	229	225	231	8.92e-44	145
k141_125659_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	39.4	226	225	231	3.55e-43	144
k141_125659_2	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.4	229	225	231	1.41e-42	142
k141_125659_2	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.0	229	225	231	7.90e-42	140
k141_125659_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	38.1	226	225	232	2.82e-39	134
k141_160463_3	SARG|YP_001571041	30.1	236	476	648	8.16e-28	115
k141_160463_3	SARG|gi|960873409|ref|WP_058345546.1|	30.1	236	476	648	8.16e-28	115
k141_160463_3	SARG|gi|740610794|ref|WP_038396317.1|	30.1	236	476	648	8.16e-28	115
k141_160463_3	SARG|gi|507044560|ref|WP_016115614.1|	34.0	215	476	306	8.88e-28	111
k141_160463_3	SARG|gi|446026113|ref|WP_000103968.1|	33.5	215	476	306	2.29e-27	110
k141_160463_3	SARG|gi|923061916|ref|WP_053445667.1|	30.5	223	476	648	2.65e-27	114
k141_160463_3	SARG|gi|746482713|ref|WP_039520502.1|	30.5	223	476	648	3.55e-27	114
k141_160463_3	SARG|gi|959866458|ref|WP_058145168.1|	30.5	223	476	648	3.55e-27	114
k141_160463_3	SARG|gi|555246906|ref|WP_023230855.1|	30.5	223	476	648	4.76e-27	113
k141_160463_3	SARG|YP_002044935	30.5	223	476	648	4.76e-27	113
k141_49202_4	SARG|gb|ABA71733.1|ARO:3002972|vanTG	38.4	365	389	712	1.81e-74	244
k141_49202_4	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	36.1	366	389	712	2.23e-66	222
k141_49202_4	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	36.4	365	389	711	4.29e-65	219
k141_49202_4	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	31.8	365	389	366	1.44e-59	196
k141_49202_4	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	34.2	357	389	700	6.27e-54	188
k141_49202_4	SARG|AAY67970	31.4	370	389	698	1.62e-53	187
k141_49202_4	SARG|AF162694.1.gene4.p01	32.3	356	389	698	8.17e-53	185
k141_49202_4	SARG|gi|657686198|ref|WP_029487032.1|	32.3	356	389	698	8.17e-53	185
k141_49202_4	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	33.7	356	389	700	2.20e-52	184
k141_49202_4	NCBI|WP_063856759.1|1|1|vanTc3|vanTc3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	33.4	356	389	700	7.22e-50	177
k141_97708_3	SARG|gi|556495988|ref|WP_023343675.1|	40.4	223	226	646	9.25e-45	157
k141_97708_3	SARG|gi|974672242|ref|WP_059256507.1|	41.6	221	226	648	9.41e-45	157
k141_97708_3	SARG|gi|974641719|ref|WP_059227752.1|	41.6	221	226	648	9.41e-45	157
k141_97708_3	SARG|gi|446110299|ref|WP_000188154.1|	41.6	221	226	648	9.41e-45	157
k141_97708_3	SARG|ZP_02903696	41.6	221	226	648	9.41e-45	157
k141_97708_3	SARG|gi|974688082|ref|WP_059271287.1|	41.6	221	226	648	9.41e-45	157
k141_97708_3	SARG|gi|823326845|ref|WP_047080664.1|	41.2	221	226	648	1.30e-44	156
k141_97708_3	SARG|gi|695793471|ref|WP_032707680.1|	41.2	221	226	648	1.30e-44	156
k141_97708_3	SARG|gi|896325272|ref|WP_049294291.1|	41.2	226	226	648	1.30e-44	156
k141_97708_3	SARG|gi|391288090|gb|EIQ46599.1|	42.1	221	226	645	1.75e-44	156
k141_97708_4	SARG|gi|495736522|ref|WP_008461101.1|	41.6	221	398	648	2.71e-50	178
k141_97708_4	SARG|gi|639216333|ref|WP_024554080.1|	42.1	221	398	648	2.71e-50	178
k141_97708_4	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	37.8	233	398	255	2.75e-50	169
k141_97708_4	SARG|gi|746253210|ref|WP_039301529.1|	41.6	221	398	648	3.74e-50	177
k141_97708_4	SARG|gi|657888313|ref|WP_029592374.1|	42.1	221	398	648	7.14e-50	177
k141_97708_4	SARG|gi|742378414|ref|WP_038857601.1|	44.1	211	398	647	9.75e-50	176
k141_97708_4	SARG|gi|1001720867|ref|WP_061274204.1|	41.2	221	398	648	9.87e-50	176
k141_97708_4	SARG|gi|896325272|ref|WP_049294291.1|	41.6	221	398	648	9.87e-50	176
k141_97708_4	SARG|gi|746243059|ref|WP_039291473.1|	41.6	221	398	648	1.88e-49	176
k141_97708_4	SARG|gi|639225329|ref|WP_024561799.1|	41.6	221	398	648	4.96e-49	174
k141_153636_1	SARG|gi|313614636|gb|EFR88215.1|	30.3	432	452	453	2.08e-66	218
k141_153636_1	SARG|gi|313638554|gb|EFS03703.1|	30.4	425	452	453	5.74e-66	217
k141_153636_1	SARG|gi|505177635|ref|WP_015364737.1|	29.9	438	452	451	1.45e-60	203
k141_153636_1	SARG|gi|984518628|emb|CUM21384.1|	31.9	313	452	341	7.15e-60	198
k141_153636_1	SARG|ZP_04679156	28.8	437	452	451	1.52e-59	200
k141_153636_1	SARG|gi|446573718|ref|WP_000651064.1|	29.8	440	452	451	1.60e-58	197
k141_153636_1	SARG|gi|686155635|ref|WP_031787393.1|	29.8	440	452	451	2.23e-58	197
k141_153636_1	SARG|gi|488374619|ref|WP_002444004.1|	29.3	444	452	452	2.29e-58	197
k141_153636_1	SARG|gi|1006223553|ref|WP_061745579.1|	28.8	437	452	451	4.57e-57	194
k141_153636_1	SARG|gi|516415429|ref|WP_017804827.1|	29.3	437	452	451	6.38e-57	193
k141_4114_4	CARD|gb|ABD30512.1|ARO:3000839|arlS	30.3	310	474	451	1.29e-28	116
k141_4114_4	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	26.0	300	474	370	2.11e-28	114
k141_4114_4	CARD|gb|AAD51347.1|ARO:3003067|smeS	26.9	297	474	467	7.99e-27	111
k141_4114_4	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	26.8	310	474	365	7.19e-26	107
k141_4114_4	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.8	252	474	381	1.41e-24	103
k141_4114_4	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.8	252	474	381	1.41e-24	103
k141_4114_4	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.8	250	474	381	1.92e-24	103
k141_4114_4	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.8	250	474	381	1.92e-24	103
k141_4114_4	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.0	250	474	381	2.60e-24	103
k141_4114_4	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.0	250	474	381	2.60e-24	103
k141_4114_5	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.3	216	218	219	7.09e-47	153
k141_4114_5	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.3	216	218	219	1.42e-46	152
k141_4114_5	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.3	216	218	220	1.46e-46	152
k141_4114_5	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.3	216	218	220	2.91e-46	151
k141_4114_5	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.9	225	218	231	5.62e-46	151
k141_4114_5	CARD|gb|ATC67679.1|ARO:3000838|arlR	39.2	217	218	219	5.66e-46	150
k141_4114_5	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.4	216	218	220	2.62e-44	146
k141_4114_5	SARG|ZP_02848503	38.9	216	218	221	7.59e-44	145
k141_4114_5	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	35.5	228	218	229	5.97e-42	140
k141_4114_5	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	34.5	226	218	231	1.26e-41	140
k141_139847_8	NCBI|WP_005813024.1|1|1|vanW-I|vanW-I||2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-I|AMR|glycopeptide	44.6	130	557	373	4.41e-26	108
k141_111995_8	SARG|gi|740152780|ref|WP_037997109.1|	27.6	239	313	322	3.01e-19	85.5
k141_111995_8	SARG|gb|AAB05626.1|ARO:3002943|vanHB	29.1	251	313	323	4.16e-19	85.1
k141_111995_8	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	28.6	255	313	323	5.69e-19	84.7
k141_111995_8	SARG|gi|985522333|ref|WP_060811962.1|	28.9	253	313	323	5.69e-19	84.7
k141_111995_8	SARG|AF310956.2.gene5.p01	28.6	255	313	323	7.78e-19	84.3
k141_111995_8	SARG|Q47748	29.1	251	313	323	7.78e-19	84.3
k141_111995_8	SARG|gi|498515089|ref|WP_010815296.1|	29.1	251	313	323	1.06e-18	84.0
k141_111995_8	SARG|YP_002333394	28.2	255	313	323	5.06e-18	82.0
k141_111995_8	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	27.8	234	313	323	5.06e-18	82.0
k141_150436_2	SARG|gb|CAE00499.1|ARO:3003835|cdeA	25.7	334	339	441	1.74e-25	105
k141_133072_5	SARG|NP_631702	28.6	384	391	392	4.19e-27	110
k141_133072_5	SARG|X59968.1.gene1.p01	28.6	384	391	392	5.74e-27	109
k141_133072_5	SARG|gi|2708772|gb|AAB96371.1|	26.9	249	391	391	1.03e-21	94.7
k141_133072_5	SARG|NP_044444	26.5	249	391	391	3.50e-21	93.2
k141_133072_5	SARG|AF024666.2.gene33.p01	26.5	249	391	391	3.50e-21	93.2
k141_133072_5	SARG|YP_251195	26.1	249	391	391	1.18e-20	91.7
k141_42304_2	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	46.1	217	265	481	2.22e-57	189
k141_42304_2	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	44.0	216	265	451	1.26e-56	186
k141_42304_2	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	45.6	217	265	451	3.50e-56	185
k141_42382_2	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	27.5	349	366	366	3.95e-28	112
k141_18164_3	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.4	231	252	232	1.82e-59	187
k141_18164_3	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.4	231	252	232	1.82e-59	187
k141_18164_3	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	39.5	228	252	229	1.89e-58	184
k141_18164_3	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	38.0	234	252	235	3.72e-54	173
k141_18164_3	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.7	230	252	231	6.60e-54	172
k141_18164_3	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	36.4	228	252	231	1.87e-53	171
k141_18164_3	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.4	228	252	231	1.87e-53	171
k141_18164_3	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.7	230	252	231	5.28e-53	170
k141_18164_3	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.2	230	252	231	5.28e-53	170
k141_18164_3	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.6	234	252	232	6.13e-52	167
k141_18164_4	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	25.2	266	526	368	1.19e-18	86.7
k141_18164_4	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	24.5	265	526	367	5.15e-18	84.7
k141_18164_4	megares|MEG_7502|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.1	203	526	361	2.83e-17	82.4
k141_18164_4	NCBI|WP_063856733.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	29.1	203	526	361	2.83e-17	82.4
k141_18164_4	NCBI|WP_063856743.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	30.7	176	526	361	6.83e-17	81.3
k141_18164_4	megares|MEG_7499|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	30.7	176	526	361	6.83e-17	81.3
k141_18164_4	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	26.6	199	526	370	9.89e-17	80.9
k141_18164_4	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.0	176	526	354	2.07e-16	79.7
k141_18164_4	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	26.8	265	526	365	7.31e-16	78.2
k141_18164_4	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	26.5	189	526	380	1.46e-15	77.4
k141_53137_1	SARG|Q83LR7	40.7	221	237	648	4.21e-54	182
k141_53137_1	SARG|gi|647325472|ref|WP_025760953.1|	40.7	221	237	648	4.21e-54	182
k141_53137_1	SARG|gi|647323678|ref|WP_025760497.1|	40.7	221	237	648	4.21e-54	182
k141_53137_1	SARG|gi|1001720867|ref|WP_061274204.1|	41.6	221	237	648	5.85e-54	182
k141_53137_1	SARG|gi|446110305|ref|WP_000188160.1|	40.3	221	237	648	1.57e-53	181
k141_53137_1	SARG|gi|495736522|ref|WP_008461101.1|	41.2	221	237	648	3.04e-53	180
k141_53137_1	SARG|gi|746253210|ref|WP_039301529.1|	41.2	221	237	648	3.04e-53	180
k141_53137_1	SARG|gi|446110301|ref|WP_000188156.1|	40.3	221	237	648	4.23e-53	180
k141_53137_1	SARG|gi|446110287|ref|WP_000188142.1|	39.2	232	237	648	5.88e-53	179
k141_53137_1	SARG|gi|803568669|ref|WP_046077412.1|	41.6	221	237	648	8.17e-53	179
k141_70753_3	SARG|gb|MBY8651253.1|ARO:3007189|vanP	38.9	350	353	342	1.75e-74	233
k141_70753_3	SARG|gi|1028100561|ref|WP_063856696.1|	39.6	356	353	349	2.14e-74	233
k141_70753_3	SARG|gi|752682279|ref|WP_041330231.1|	39.0	356	353	349	2.40e-73	230
k141_70753_3	SARG|DQ212986.1.gene8.p01	38.5	356	353	349	3.78e-72	227
k141_70753_3	NCBI|WP_015943583.1|1|1|vanI|vanI|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--(R)-lactate_ligase_VanI|AMR|glycopeptide	39.2	357	353	341	4.23e-72	226
k141_70753_3	SARG|gi|405945042|pdb|4FU0|A	38.5	356	353	357	4.76e-72	227
k141_70753_3	SARG|AAD42184	37.9	356	353	343	8.94e-72	226
k141_70753_3	SARG|gi|765411304|ref|WP_044689514.1|	38.5	356	353	349	1.06e-71	226
k141_70753_3	SARG|gi|552941803|ref|WP_023042860.1|	37.9	356	353	343	1.78e-71	225
k141_70753_3	SARG|AAF71281	38.2	356	353	349	2.12e-71	225
k141_143817_1	SARG|gb|WP_104671188.1|ARO:3003948|efrA	39.3	504	503	575	3.76e-99	309
k141_143817_1	SARG|gb|AAK76137.1|ARO:3000024|patA	31.1	511	503	564	1.24e-74	244
k141_143817_1	SARG|gb|AAC74000.1|ARO:3003950|msbA	27.2	497	503	582	6.00e-48	173
k141_143817_1	SARG|gi|917229923|ref|WP_051836635.1|	27.0	508	503	620	1.63e-45	167
k141_143817_1	SARG|gi|917155568|ref|WP_051762280.1|	27.0	508	503	620	5.78e-45	166
k141_143817_1	SARG|gi|501350226|ref|WP_012381861.1|	27.0	508	503	603	6.49e-45	165
k141_143817_1	SARG|gi|772774655|ref|WP_045322518.1|	35.9	309	503	620	7.93e-45	165
k141_143817_1	SARG|gi|943938624|ref|WP_055567802.1|	26.2	507	503	602	1.21e-44	164
k141_143817_1	SARG|gi|664170108|ref|WP_030704355.1|	27.0	508	503	603	1.22e-44	164
k141_143817_1	SARG|gi|799286378|ref|WP_045936958.1|	35.3	309	503	620	1.49e-44	164
k141_56760_8	SARG|gi|928900436|ref|WP_053931243.1|	33.5	501	597	600	3.19e-70	236
k141_56760_8	SARG|gi|664579989|ref|WP_031094015.1|	33.5	501	597	601	3.26e-70	236
k141_56760_8	SARG|gi|516574297|ref|WP_017949361.1|	32.5	504	597	620	4.88e-69	234
k141_56760_8	SARG|gi|947982677|ref|WP_056642336.1|	34.5	504	597	626	7.65e-69	233
k141_56760_8	SARG|gi|639892676|ref|WP_024755698.1|	34.5	504	597	631	8.44e-69	233
k141_56760_8	SARG|gi|664042835|ref|WP_030582300.1|	32.7	501	597	604	1.84e-68	232
k141_56760_8	SARG|gi|944152509|ref|WP_055644808.1|	33.7	516	597	616	2.35e-68	232
k141_56760_8	SARG|gi|517347347|ref|WP_018522839.1|	32.9	501	597	601	3.35e-68	231
k141_56760_8	SARG|gi|926356413|ref|WP_053687351.1|	33.5	502	597	620	6.83e-68	231
k141_56760_8	SARG|gi|926294973|ref|WP_053631154.1|	33.5	502	597	620	6.83e-68	231
k141_56760_9	SARG|gi|497748188|ref|WP_010062372.1|	28.6	535	578	605	9.02e-63	216
k141_56760_9	SARG|gb|AAC74000.1|ARO:3003950|msbA	29.6	503	578	582	4.05e-59	206
k141_56760_9	SARG|gi|943909899|ref|WP_055545300.1|	28.0	553	578	601	7.52e-57	200
k141_56760_9	SARG|gb|AAK76136.1|ARO:3000025|patB	30.1	489	578	588	1.15e-56	199
k141_56760_9	SARG|gi|496018010|ref|WP_008742581.1|	28.2	543	578	623	1.44e-55	197
k141_56760_9	SARG|gi|926351744|ref|WP_053683383.1|	27.7	538	578	648	2.11e-55	197
k141_56760_9	SARG|gi|943896259|ref|WP_055534530.1|	27.1	550	578	601	3.67e-55	195
k141_56760_9	SARG|gb|AYV52072.1|ARO:3002882|lmrD	29.4	496	578	664	5.06e-55	196
k141_56760_9	SARG|gi|944470764|ref|WP_055701183.1|	40.9	242	578	601	1.84e-54	193
k141_56760_9	SARG|gi|664244930|ref|WP_030776974.1|	26.9	550	578	601	4.85e-54	192
k141_101965_3	SARG|AUI09862.1	46.0	278	269	287	1.51e-78	238
k141_101965_3	SARG|AJ459418.gene.p01	33.7	261	269	263	2.32e-38	134
k141_101965_3	SARG|gi|970263436|ref|WP_058647620.1|	33.7	261	269	263	3.26e-38	134
k141_101965_3	SARG|gi|553729091|ref|WP_023063817.1|	30.6	252	269	271	3.02e-32	118
k141_101965_3	SARG|gi|754661150|ref|WP_042043527.1|	30.2	252	269	271	8.30e-32	117
k141_101965_3	SARG|gi|550552396|ref|WP_022631488.1|	30.6	252	269	271	8.30e-32	117
k141_101965_3	SARG|gi|504199703|ref|WP_014386805.1|	30.2	252	269	271	8.30e-32	117
k141_101965_3	SARG|gi|916164813|ref|WP_050960181.1|	30.2	252	269	271	1.16e-31	117
k141_101965_3	SARG|gi|846280841|gb|AKN19373.1|	30.2	255	269	279	1.38e-31	117
k141_101965_3	SARG|gi|836556079|ref|WP_047715692.1|	30.2	252	269	271	1.63e-31	116
k141_147244_3	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	62.5	24	27	255	2.91e-06	39.3
k141_157469_5	NCBI|WP_063856927.1|1|1|vanZ-Pt|vanZ-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_protein_VanZ-Pt|AMR|glycopeptide	38.5	104	159	159	5.16e-13	62.0
k141_157469_5	SARG|gi|515720450|ref|WP_017153050.1|	37.7	77	159	210	1.13e-10	56.6
k141_157469_5	SARG|gi|1028848471|ref|WP_064017434.1|	35.1	77	159	206	1.04e-09	53.9
k141_157469_5	SARG|gi|670466162|ref|WP_031414939.1|	35.1	77	159	206	1.43e-09	53.5
k141_157469_5	SARG|AF155139.2.gene5.p01	25.7	140	159	206	1.98e-09	53.1
k141_129868_4	SARG|gb|AAV85982.1|ARO:3000535|macB	24.4	450	428	644	3.03e-12	67.4
k141_129868_4	SARG|gi|487410704|ref|WP_001678420.1|	32.9	152	428	648	4.03e-12	67.0
k141_129868_4	SARG|gi|485866062|ref|WP_001464282.1|	32.2	152	428	648	1.25e-11	65.5
k141_129868_4	SARG|gi|693066875|ref|WP_032232318.1|	32.2	152	428	648	1.65e-11	65.1
k141_129868_4	SARG|gi|486188371|ref|WP_001542171.1|	31.8	154	428	648	1.65e-11	65.1
k141_129868_4	SARG|gi|495067432|ref|WP_007792257.1|	23.8	442	428	647	2.19e-11	64.7
k141_129868_4	SARG|gi|693106883|ref|WP_032260279.1|	32.2	152	428	648	2.19e-11	64.7
k141_129868_4	SARG|gi|1016544759|ref|WP_063115144.1|	32.2	152	428	648	2.19e-11	64.7
k141_129868_4	SARG|gi|971845730|ref|WP_058914924.1|	32.2	152	428	648	2.19e-11	64.7
k141_129868_4	SARG|gi|976150970|ref|WP_059309182.1|	32.2	152	428	648	2.19e-11	64.7
k141_129868_6	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	42.5	219	226	255	7.42e-60	187
k141_129868_6	SARG|gi|696368937|ref|WP_032943949.1|	42.5	219	226	648	3.96e-55	185
k141_129868_6	SARG|gi|851913025|ref|WP_048215946.1|	42.5	219	226	648	3.96e-55	185
k141_129868_6	SARG|gi|489930965|ref|WP_003834285.1|	42.5	219	226	648	3.96e-55	185
k141_129868_6	SARG|gi|696361545|ref|WP_032936694.1|	42.5	219	226	648	5.51e-55	184
k141_129868_6	SARG|gi|489936909|ref|WP_003840216.1|	42.5	219	226	648	5.51e-55	184
k141_129868_6	SARG|gi|507079862|ref|WP_016150620.1|	42.5	219	226	648	5.51e-55	184
k141_129868_6	SARG|gi|949791377|ref|WP_057104572.1|	42.5	219	226	648	5.51e-55	184
k141_129868_6	SARG|gi|936194420|ref|WP_054528571.1|	42.5	219	226	648	7.67e-55	184
k141_129868_6	SARG|YP_002850060	42.5	219	226	648	7.67e-55	184
k141_129888_4	SARG|gb|AAD01868.1|ARO:3002867|dfrF	71.8	156	159	164	1.68e-79	231
k141_129888_4	NCBI|WP_012655890.1|1|1|dfrE|dfrE|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrE|AMR|diaminopyrimidine	47.1	157	159	164	4.30e-44	142
k141_129888_4	SARG|CAX16467	41.4	157	159	165	5.68e-37	124
k141_129888_4	NCBI|WP_071846242.1|1|1|dfrA33|dfrA33|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA33|AMR|diaminopyrimidine	41.4	157	159	165	8.05e-37	123
k141_129888_4	SARG|gb|WP_149100971.1|ARO:3005351|DfrA39	41.4	157	159	165	1.14e-36	123
k141_129888_4	NCBI|WP_071846282.1|1|1|dfrA12|dfrA12|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA12|AMR|diaminopyrimidine	42.0	157	159	165	3.23e-36	122
k141_129888_4	SARG|gb|CAF31623.1|ARO:3005354|dfr22	40.1	157	159	165	9.17e-36	120
k141_129888_4	SARG|gb|AGY30828.1|ARO:3003018|dfrA22	40.8	157	159	165	9.17e-36	120
k141_129888_4	SARG|BAD77819	42.0	157	159	165	1.30e-35	120
k141_129888_4	SARG|AAT45231	41.4	157	159	165	2.60e-35	119
k141_129888_6	CARD|gb|ABD30512.1|ARO:3000839|arlS	33.2	250	433	451	2.99e-36	137
k141_129888_6	CARD|gb|BAB38260.1|ARO:3000830|cpxA	28.5	253	433	457	2.00e-24	103
k141_129888_6	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	27.6	250	433	388	1.19e-23	100
k141_129888_6	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	27.6	250	433	388	1.19e-23	100
k141_129888_6	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	27.2	250	433	386	5.40e-23	99.0
k141_129888_6	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	27.2	250	433	386	5.40e-23	99.0
k141_129888_6	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	27.6	250	433	386	1.35e-22	97.8
k141_129888_6	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	27.6	250	433	386	1.35e-22	97.8
k141_129888_6	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	28.0	250	433	382	1.75e-22	97.4
k141_129888_6	NCBI|WP_063856731.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	28.0	250	433	382	1.75e-22	97.4
k141_129888_7	CARD|gb|ATC67679.1|ARO:3000838|arlR	53.6	222	228	219	2.73e-75	226
k141_129888_7	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.2	233	228	232	5.64e-49	159
k141_129888_7	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	40.8	233	228	232	1.59e-48	158
k141_129888_7	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	41.7	223	228	231	1.74e-47	155
k141_129888_7	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.5	232	228	231	9.83e-47	153
k141_129888_7	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	40.1	232	228	231	2.77e-46	152
k141_129888_7	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.1	232	228	231	6.21e-45	149
k141_129888_7	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.5	224	228	232	1.27e-44	148
k141_129888_7	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	38.1	223	228	228	3.21e-44	147
k141_129888_7	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.9	232	228	231	3.90e-43	144
k141_140644_3	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	24.1	166	156	359	8.80e-07	46.2
k141_1669_2	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	28.1	263	437	355	3.14e-17	81.6
k141_1669_2	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	28.1	263	437	355	3.14e-17	81.6
k141_1669_2	SARG|ACM47285	28.1	263	437	363	3.37e-17	81.6
k141_1669_2	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	27.0	263	437	355	1.03e-16	80.1
k141_1669_2	SARG|BAE96115	27.0	263	437	355	1.03e-16	80.1
k141_1669_2	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	26.6	263	437	356	1.10e-15	77.0
k141_1669_2	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	27.0	263	437	356	1.48e-15	76.6
k141_1669_2	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	27.2	195	437	209	1.45e-10	59.7
k141_8326_2	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	32.3	124	245	252	8.83e-11	59.3
k141_8326_2	CARD|gb|AAG06465.1|ARO:3005063|cprR	34.2	73	245	223	2.68e-07	48.9
k141_8326_5	SARG|gi|542061059|gb|ERI11611.1|	26.5	226	503	316	2.64e-21	93.6
k141_8326_5	SARG|P42332	27.4	223	503	306	1.04e-20	91.7
k141_8326_5	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	27.4	223	503	306	1.04e-20	91.7
k141_8326_5	SARG|gi|510143239|gb|AGN36970.1|	27.4	223	503	313	1.15e-20	91.7
k141_8326_5	SARG|ABB80128	27.4	223	503	306	1.40e-20	91.3
k141_8326_5	SARG|AAD21213	27.4	223	503	306	3.48e-20	90.1
k141_8326_5	SARG|YP_001373621	26.1	222	503	318	4.13e-20	90.1
k141_8326_5	SARG|gb|AYV52072.1|ARO:3002882|lmrD	27.3	220	503	664	4.82e-13	70.5
k141_8326_5	SARG|gi|1035717981|ref|WP_064557480.1|	25.0	212	503	648	4.44e-12	67.4
k141_8326_5	SARG|gi|1035670474|ref|WP_064517458.1|	25.1	207	503	648	5.87e-12	67.0
k141_8326_7	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	22.2	135	535	228	6.01e-06	46.6
k141_8326_7	CARD|gb|BAB36671.1|ARO:3000832|evgA	30.6	85	535	204	8.60e-06	45.8
k141_57080_2	SARG|YP_001373621	39.8	221	241	318	1.90e-46	155
k141_57080_2	SARG|gi|542061059|gb|ERI11611.1|	35.7	221	241	316	4.27e-40	139
k141_57080_2	SARG|gi|739906046|ref|WP_037756452.1|	20.5	210	241	620	3.67e-09	55.5
k141_57080_2	SARG|gi|516574297|ref|WP_017949361.1|	20.4	211	241	620	3.67e-09	55.5
k141_91912_1	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	29.1	203	815	365	5.36e-20	91.7
k141_91912_1	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	28.6	203	815	370	1.37e-19	90.5
k141_91912_1	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.9	173	815	376	9.00e-17	82.0
k141_91912_1	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	28.9	173	815	376	9.00e-17	82.0
k141_91912_1	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	30.2	159	815	352	9.49e-17	81.6
k141_91912_1	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.4	163	815	381	4.00e-16	80.1
k141_91912_1	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.4	163	815	381	4.00e-16	80.1
k141_91912_1	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.8	153	815	354	7.48e-16	79.0
k141_91912_1	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.8	153	815	354	1.00e-15	78.6
k141_91912_1	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.4	169	815	381	2.27e-15	77.8
k141_91912_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	46.1	228	278	232	2.61e-71	218
k141_91912_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	46.1	228	278	232	2.61e-71	218
k141_91912_2	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	45.5	231	278	239	6.54e-71	217
k141_91912_2	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	46.3	229	278	233	3.08e-70	215
k141_91912_2	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	45.1	226	278	231	3.76e-68	210
k141_91912_2	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	45.1	226	278	231	3.76e-68	210
k141_91912_2	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	45.1	226	278	231	2.14e-67	208
k141_91912_2	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	44.7	226	278	231	3.03e-67	207
k141_91912_2	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	44.3	230	278	235	3.43e-67	207
k141_91912_2	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	45.2	228	278	229	5.69e-67	207
k141_164947_1	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.8	221	227	232	8.65e-42	140
k141_164947_1	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.8	221	227	232	8.65e-42	140
k141_164947_1	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.0	211	227	231	2.93e-39	134
k141_164947_1	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.2	210	227	231	4.57e-38	131
k141_164947_1	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.7	210	227	231	1.28e-37	130
k141_164947_1	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	35.1	211	227	231	2.55e-37	129
k141_164947_1	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.1	211	227	231	2.55e-37	129
k141_164947_1	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	37.2	215	227	239	2.68e-35	124
k141_164947_1	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	40.8	184	227	228	2.86e-35	124
k141_164947_1	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.6	216	227	231	6.13e-35	123
k141_130213_4	SARG|gi|960873409|ref|WP_058345546.1|	36.1	241	355	648	1.10e-42	155
k141_130213_4	SARG|YP_001571041	36.6	224	355	648	1.52e-42	155
k141_130213_4	SARG|gi|740610794|ref|WP_038396317.1|	36.1	241	355	648	2.87e-42	154
k141_130213_4	SARG|gi|923061916|ref|WP_053445667.1|	36.6	224	355	648	7.44e-42	153
k141_130213_4	SARG|gi|555268367|ref|WP_023249730.1|	36.1	241	355	648	1.02e-41	153
k141_130213_4	SARG|gi|1027935297|ref|WP_063809363.1|	36.1	241	355	648	1.02e-41	153
k141_130213_4	SARG|gi|555246906|ref|WP_023230855.1|	36.6	224	355	648	1.40e-41	152
k141_130213_4	SARG|YP_002044935	36.6	224	355	648	1.40e-41	152
k141_130213_4	SARG|gi|835666879|ref|WP_047606339.1|	36.6	224	355	648	1.40e-41	152
k141_130213_4	SARG|gi|685236936|ref|WP_031605176.1|	36.6	224	355	648	1.40e-41	152
k141_64066_2	CARD|gb|WKR28567.1|ARO:3007678|IreK	32.0	699	740	718	3.90e-81	272
k141_12155_1	CARD|gb|AAD51347.1|ARO:3003067|smeS	30.9	278	502	467	4.02e-35	135
k141_12155_1	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	26.8	265	502	370	4.35e-29	117
k141_12155_1	CARD|gb|CYF42523.1|ARO:3004047|kdpD	28.7	223	502	885	6.21e-20	92.4
k141_12155_1	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	24.1	224	502	341	5.87e-14	72.0
k141_12155_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	44.4	234	239	228	1.22e-63	197
k141_12155_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	45.5	235	239	231	3.08e-62	193
k141_12155_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	44.5	238	239	232	9.00e-62	192
k141_12155_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.4	237	239	232	3.90e-55	175
k141_12155_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.4	237	239	232	3.90e-55	175
k141_12155_2	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	40.9	235	239	231	1.07e-54	174
k141_12155_2	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	40.9	237	239	235	1.37e-53	171
k141_12155_2	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	40.7	236	239	231	6.87e-53	169
k141_12155_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	39.1	233	239	219	2.72e-52	167
k141_12155_2	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.6	235	239	231	2.75e-52	168
k141_57526_1	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	32.6	92	143	574	1.55e-07	48.1
k141_57526_1	SARG|gb|CDO61516.1|ARO:3003949|efrB	32.3	62	143	362	3.03e-06	44.3
k141_106015_2	SARG|YP_002850060	37.7	244	260	648	7.42e-44	155
k141_106015_2	SARG|gi|851913025|ref|WP_048215946.1|	37.7	244	260	648	1.41e-43	155
k141_106015_2	SARG|gi|489930965|ref|WP_003834285.1|	37.7	244	260	648	1.41e-43	155
k141_106015_2	SARG|gi|936194420|ref|WP_054528571.1|	37.7	244	260	648	1.95e-43	154
k141_106015_2	SARG|gi|696368937|ref|WP_032943949.1|	37.9	243	260	648	1.95e-43	154
k141_106015_2	SARG|gi|489936909|ref|WP_003840216.1|	37.7	244	260	648	1.95e-43	154
k141_106015_2	SARG|gi|507079862|ref|WP_016150620.1|	37.7	244	260	648	1.95e-43	154
k141_106015_2	SARG|gi|949791377|ref|WP_057104572.1|	37.7	244	260	648	1.95e-43	154
k141_106015_2	SARG|gi|696361545|ref|WP_032936694.1|	37.9	243	260	648	2.69e-43	154
k141_106015_2	SARG|gi|851922185|ref|WP_048218206.1|	37.7	244	260	648	5.12e-43	153
k141_50479_1	SARG|gi|488374619|ref|WP_002444004.1|	23.0	431	455	452	3.01e-35	135
k141_126663_1	CARD|gb|AAC75429.1|ARO:3000833|evgS	27.8	367	626	1197	5.33e-38	150
k141_126663_1	CARD|gb|CYF42523.1|ARO:3004047|kdpD	29.9	224	626	885	3.79e-19	90.9
k141_126663_1	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	28.8	222	626	364	6.61e-19	87.8
k141_126663_1	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	28.8	222	626	364	6.61e-19	87.8
k141_126663_1	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.1	221	626	352	6.09e-18	84.7
k141_126663_1	CARD|gb|AEX49906.1|ARO:3003583|basS	27.9	244	626	477	8.69e-18	85.5
k141_126663_1	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.1	221	626	354	3.62e-17	82.4
k141_126663_1	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	26.7	221	626	376	1.07e-16	81.3
k141_126663_1	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	26.7	221	626	376	1.07e-16	81.3
k141_126663_1	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	26.7	221	626	354	1.56e-16	80.5
k141_126663_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	38.7	124	128	228	4.62e-25	94.0
k141_126663_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	36.8	117	128	232	1.88e-20	82.0
k141_126663_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.8	117	128	231	7.12e-20	80.5
k141_126663_2	CARD|gb|ADM92605.1|ARO:3000553|adeR	31.4	118	128	247	2.79e-16	71.2
k141_126663_2	CARD|gb|AAG05188.1|ARO:3005068|ParR	31.0	116	128	235	9.01e-16	69.7
k141_126663_2	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	31.9	116	128	225	1.15e-12	61.2
k141_126663_2	CARD|gb|AAC73788.1|ARO:3003841|kdpE	31.9	116	128	225	1.15e-12	61.2
k141_126663_2	CARD|gb|BAB36671.1|ARO:3000832|evgA	29.7	118	128	204	9.04e-12	58.5
k141_126663_2	CARD|gb|AAG06465.1|ARO:3005063|cprR	31.4	118	128	223	1.10e-10	55.8
k141_126663_2	CARD|gb|AAC75429.1|ARO:3000833|evgS	24.2	120	128	1197	1.50e-07	47.8
k141_67579_2	SARG|gb|MBW0770001.1|ARO:3007026|salB	40.9	66	86	541	3.59e-08	47.8
k141_85587_6	SARG|gb|AAK76136.1|ARO:3000025|patB	33.9	623	642	588	7.62e-102	321
k141_85587_6	SARG|gb|AYV52072.1|ARO:3002882|lmrD	34.2	544	642	664	3.09e-94	303
k141_85587_6	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	30.1	622	642	579	1.11e-80	265
k141_85587_6	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	29.6	625	642	579	1.61e-79	262
k141_85587_6	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	31.5	623	642	578	1.25e-76	254
k141_85587_6	SARG|gb|CDO61516.1|ARO:3003949|efrB	33.9	392	642	362	1.17e-71	234
k141_85587_6	SARG|gi|497748188|ref|WP_010062372.1|	29.3	614	642	605	4.89e-71	240
k141_85587_6	SARG|gi|1045390184|ref|WP_065479071.1|	29.2	614	642	605	1.83e-70	238
k141_85587_6	SARG|gi|948040364|ref|WP_056699531.1|	29.3	614	642	603	2.44e-70	238
k141_85587_6	SARG|gi|695865802|ref|WP_032778631.1|	29.2	614	642	605	3.54e-70	238
k141_85587_7	SARG|gb|WP_104671188.1|ARO:3003948|efrA	37.3	456	465	575	4.74e-91	286
k141_85587_7	SARG|gb|AAK76137.1|ARO:3000024|patA	34.8	457	465	564	5.30e-82	263
k141_85587_7	SARG|gi|748767925|ref|WP_040019608.1|	40.0	315	465	623	5.49e-68	227
k141_85587_7	SARG|gi|695887424|ref|WP_032788534.1|	39.4	320	465	605	2.17e-65	220
k141_85587_7	SARG|gi|1045390184|ref|WP_065479071.1|	39.9	318	465	605	3.03e-65	219
k141_85587_7	SARG|gi|764446018|ref|WP_044369325.1|	39.6	318	465	605	8.23e-65	218
k141_85587_7	SARG|gi|497748188|ref|WP_010062372.1|	39.6	318	465	605	1.60e-64	218
k141_85587_7	SARG|gi|664180077|ref|WP_030714054.1|	39.7	315	465	605	3.11e-64	217
k141_85587_7	SARG|gi|926400371|ref|WP_053728483.1|	44.0	259	465	603	4.17e-64	216
k141_85587_7	SARG|gi|695865802|ref|WP_032778631.1|	39.0	318	465	605	6.04e-64	216
k141_33293_2	CARD|gb|ABD30512.1|ARO:3000839|arlS	32.2	245	376	451	3.04e-33	127
k141_33293_2	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.5	246	376	381	1.39e-23	99.8
k141_33293_2	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.5	246	376	381	1.39e-23	99.8
k141_33293_2	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.6	247	376	381	3.54e-23	98.6
k141_33293_2	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.6	247	376	381	3.54e-23	98.6
k141_33293_2	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.5	239	376	381	4.21e-22	95.5
k141_33293_2	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.5	239	376	381	4.21e-22	95.5
k141_33293_2	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.8	246	376	381	7.80e-22	94.7
k141_33293_2	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.8	246	376	381	7.80e-22	94.7
k141_33293_2	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	25.0	224	376	392	8.43e-20	89.0
k141_102994_1	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.0	527	526	655	4.68e-70	235
k141_102994_1	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.0	527	526	655	4.68e-70	235
k141_102994_1	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.8	527	526	655	1.27e-69	234
k141_102994_1	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.0	527	526	655	1.76e-69	234
k141_102994_1	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.0	527	526	655	2.45e-69	233
k141_102994_1	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.8	527	526	655	2.45e-69	233
k141_102994_1	SARG|gb|AKA86814|ARO:3003746|optrA	29.8	527	526	655	2.45e-69	233
k141_102994_1	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.8	527	526	655	6.63e-69	232
k141_102994_1	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.8	527	526	655	6.63e-69	232
k141_102994_1	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.8	527	526	655	6.63e-69	232
k141_162285_2	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	29.8	362	901	633	1.18e-25	112
k141_99243_1	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	34.6	104	120	293	4.30e-13	62.8
k141_99243_1	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	36.5	96	120	307	2.09e-11	58.2
k141_99243_1	SARG|ZP_04081918	31.1	103	120	306	2.83e-08	49.3
k141_99243_1	SARG|gi|445996709|ref|WP_000074564.1|	31.7	104	120	309	2.85e-08	49.3
k141_99243_1	SARG|gi|895736250|emb|COF64653.1|	31.7	104	120	309	2.85e-08	49.3
k141_99243_1	SARG|gi|446110087|ref|WP_000187942.1|	31.7	104	120	309	2.85e-08	49.3
k141_99243_1	SARG|gi|445996710|ref|WP_000074565.1|	31.7	104	120	309	2.85e-08	49.3
k141_99243_1	SARG|gi|814314593|emb|CKF49145.1|	31.7	104	120	309	2.85e-08	49.3
k141_99243_1	SARG|gi|895808656|emb|COR83787.1|	31.7	104	120	309	2.85e-08	49.3
k141_99243_1	SARG|gi|447195836|ref|WP_001273092.1|	31.1	103	120	306	3.87e-08	48.9
k141_96438_2	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	43.1	225	229	229	6.07e-59	184
k141_96438_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	43.2	227	229	232	2.15e-57	181
k141_96438_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	41.6	226	229	231	1.68e-56	178
k141_96438_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.5	224	229	232	3.46e-56	177
k141_96438_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.5	224	229	232	3.46e-56	177
k141_96438_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	38.8	227	229	219	4.68e-56	177
k141_96438_2	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	40.5	227	229	231	4.75e-56	177
k141_96438_2	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	44.4	225	229	233	1.01e-55	176
k141_96438_2	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	40.5	227	229	231	1.35e-55	176
k141_96438_2	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	40.5	227	229	231	1.90e-55	176
k141_151914_1	CARD|gb|AAC75429.1|ARO:3000833|evgS	38.8	209	383	1197	9.28e-32	126
k141_29744_2	SARG|gi|748767925|ref|WP_040019608.1|	26.3	224	254	623	4.93e-12	64.3
k141_29744_2	SARG|gb|AAK76136.1|ARO:3000025|patB	27.5	222	254	588	2.13e-11	62.4
k141_29744_2	SARG|gi|926400371|ref|WP_053728483.1|	29.3	188	254	603	3.89e-11	61.6
k141_29744_2	SARG|gi|664556405|ref|WP_031071225.1|	26.1	222	254	602	1.27e-10	60.1
k141_29744_2	SARG|AF170880.4.gene1.p01	27.1	236	254	615	1.72e-10	59.7
k141_29744_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	27.8	237	254	664	1.77e-10	59.7
k141_29744_2	SARG|gi|558888514|ref|WP_023543283.1|	26.7	240	254	615	3.11e-10	58.9
k141_29744_2	SARG|gi|664352659|ref|WP_030880307.1|	26.3	228	254	601	4.15e-10	58.5
k141_29744_2	SARG|gi|702897513|ref|WP_033300957.1|	26.5	226	254	601	4.15e-10	58.5
k141_29744_2	SARG|gi|655401130|ref|WP_028800283.1|	26.6	222	254	599	7.48e-10	57.8
k141_130948_4	SARG|gi|736472622|ref|WP_034494292.1|	40.1	222	229	648	2.63e-43	153
k141_130948_4	SARG|gi|502669352|ref|WP_012905216.1|	38.2	220	229	648	6.90e-43	152
k141_130948_4	SARG|gi|1035706844|ref|WP_064548272.1|	40.5	222	229	648	6.90e-43	152
k141_130948_4	SARG|gi|803568669|ref|WP_046077412.1|	37.8	222	229	648	2.50e-42	150
k141_130948_4	SARG|gi|446110352|ref|WP_000188207.1|	37.8	222	229	648	2.50e-42	150
k141_130948_4	SARG|YP_002382193	37.8	222	229	648	2.50e-42	150
k141_130948_4	SARG|gi|803575554|ref|WP_046081557.1|	37.8	222	229	648	2.50e-42	150
k141_130948_4	SARG|gi|446110351|ref|WP_000188206.1|	37.8	222	229	648	2.50e-42	150
k141_130948_4	SARG|gi|1035670474|ref|WP_064517458.1|	39.6	222	229	648	3.45e-42	150
k141_130948_4	SARG|gi|1035717981|ref|WP_064557480.1|	39.6	222	229	648	3.45e-42	150
k141_82076_1	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	25.0	673	760	1024	3.51e-31	130
k141_82076_1	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	25.0	673	760	1024	3.51e-31	130
k141_82076_1	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	25.0	673	760	1024	3.51e-31	130
k141_82076_1	SARG|gb|CAA53189|ARO:3000521|mupA	25.0	673	760	1024	3.51e-31	130
k141_82076_1	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	23.7	676	760	1033	3.07e-29	124
k141_82076_1	SARG|gb|AEY83581|ARO:3000510|mupB	23.7	676	760	1033	3.07e-29	124
k141_82076_1	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	21.4	869	760	1107	1.10e-15	80.5
k141_82076_1	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	21.4	869	760	1107	1.10e-15	80.5
k141_61137_1	NCBI|WP_005480402.1|1|1|tet(35)|tet(35)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35)|AMR|tetracycline	40.4	235	274	533	4.18e-49	169
k141_120719_4	SARG|gb|WP_009089555.1|ARO:3005669|GOB-20	29.4	143	211	290	2.68e-11	60.5
k141_120719_4	SARG|gb|AAT68577.1|ARO:3004802|GOB-10	29.4	143	211	290	2.68e-11	60.5
k141_120719_4	SARG|gb|WP_058879139.1|ARO:3005687|GOB-38	29.4	143	211	290	2.68e-11	60.5
k141_120719_4	SARG|gb|AAQ54756.1|ARO:3004815|GOB-8	29.4	143	211	290	2.68e-11	60.5
k141_120719_4	SARG|gb|AAT68576.1|ARO:3004816|GOB-9	29.4	143	211	290	2.68e-11	60.5
k141_120719_4	megares|MEG_3165|Drugs|beta-lactam|Class_B_betalactamases|GOB_1	29.4	143	211	290	9.22e-11	58.9
k141_120719_4	SARG|gb|WP_078675023.1|ARO:3005698|GOB-50	29.4	143	211	290	9.22e-11	58.9
k141_120719_4	SARG|gb|AJP77054|ARO:3003716|CPS-1	29.4	143	211	290	9.22e-11	58.9
k141_120719_4	SARG|gb|AAF89147.1|ARO:3004810|GOB-3	29.4	143	211	252	9.79e-11	58.5
k141_120719_4	NCBI|WP_078411523.1|1|1|blaGOB-3|blaGOB|hydrolase|2|||subclass_B3_metallo-beta-lactamase_GOB-3|AMR|beta-lactam	29.4	143	211	290	1.26e-10	58.5
k141_148686_1	NCBI|WP_002368696.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	30.0	320	357	447	2.39e-31	122
k141_148686_1	NCBI|WP_002382867.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	29.1	320	357	447	6.23e-31	120
k141_148686_1	NCBI|WP_012579101.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	29.1	320	357	447	6.23e-31	120
k141_148686_1	NCBI|WP_063856739.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	29.1	320	357	447	6.23e-31	120
k141_148686_1	NCBI|WP_063856751.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	27.5	320	357	454	7.83e-29	115
k141_148686_2	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	48.1	187	183	703	3.83e-49	167
k141_103410_6	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	30.9	204	643	255	1.30e-22	96.7
k141_103410_6	SARG|gi|949802831|ref|WP_057109467.1|	32.7	220	643	648	1.10e-21	98.6
k141_103410_6	SARG|gi|446110263|ref|WP_000188118.1|	32.7	220	643	648	1.46e-21	98.2
k141_103410_6	SARG|gi|1016521294|ref|WP_063100554.1|	32.1	218	643	648	1.46e-21	98.2
k141_103410_6	SARG|gi|643601187|ref|WP_025237288.1|	31.2	218	643	648	1.94e-21	97.8
k141_103410_6	SARG|gi|974628291|ref|WP_059215695.1|	31.2	218	643	648	1.94e-21	97.8
k141_103410_6	SARG|gi|446110298|ref|WP_000188153.1|	31.2	218	643	648	1.94e-21	97.8
k141_103410_6	SARG|gi|1035686596|ref|WP_064530178.1|	31.7	218	643	648	1.94e-21	97.8
k141_103410_6	SARG|gi|974633183|ref|WP_059219858.1|	31.2	218	643	648	1.94e-21	97.8
k141_103410_6	SARG|gi|510923671|ref|WP_016244456.1|	33.9	218	643	648	1.94e-21	97.8
k141_148768_1	SARG|gb|CDO61516.1|ARO:3003949|efrB	62.2	201	262	362	1.07e-83	253
k141_148768_1	SARG|gb|AYV52072.1|ARO:3002882|lmrD	52.3	241	262	664	3.28e-79	250
k141_148768_1	SARG|gb|AAK76136.1|ARO:3000025|patB	51.9	237	262	588	9.92e-79	247
k141_148768_1	SARG|gi|817122037|ref|WP_046494699.1|	48.4	246	262	613	5.66e-71	228
k141_148768_1	SARG|gi|928900436|ref|WP_053931243.1|	48.6	245	262	600	8.60e-71	227
k141_148768_1	SARG|gi|664579989|ref|WP_031094015.1|	48.6	245	262	601	8.78e-71	227
k141_148768_1	SARG|gi|947982677|ref|WP_056642336.1|	48.6	245	262	626	1.02e-70	227
k141_148768_1	SARG|gi|639892676|ref|WP_024755698.1|	48.6	245	262	631	1.12e-70	227
k141_148768_1	SARG|gi|1033217078|gb|OAR27197.1|	48.2	245	262	601	1.73e-70	226
k141_148768_1	SARG|gi|748767925|ref|WP_040019608.1|	48.6	245	262	623	1.90e-70	226
k141_135137_2	CARD|gb|AAD51347.1|ARO:3003067|smeS	31.5	292	383	467	3.95e-32	125
k141_135137_2	SARG|gb|AAG05187.1|ARO:3005067|ParS	31.1	244	383	428	1.77e-28	114
k141_135137_2	CARD|gb|ADM92606.1|ARO:3000549|adeS	29.5	244	383	361	1.46e-22	96.7
k141_135137_2	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	25.9	232	383	364	2.73e-18	84.3
k141_135137_2	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	25.9	232	383	364	2.73e-18	84.3
k141_135137_2	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	24.9	233	383	364	1.82e-16	79.0
k141_135137_2	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	24.9	233	383	364	1.82e-16	79.0
k141_48356_4	CARD|gb|AAC75429.1|ARO:3000833|evgS	30.2	116	506	1197	2.76e-07	52.4
k141_48356_4	CARD|gb|BAB36671.1|ARO:3000832|evgA	28.7	122	506	204	4.07e-07	49.7
k141_82369_7	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	23.3	464	500	481	1.23e-20	93.6
k141_82369_7	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	24.6	398	500	451	6.18e-17	82.0
k141_93050_4	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	31.4	318	313	343	6.71e-48	162
k141_93050_4	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	32.3	316	313	325	2.56e-46	158
k141_93050_4	SARG|gb|AAA26793|ARO:3003748|oleC	32.5	314	313	325	5.04e-46	157
k141_93050_4	SARG|gb|ADZ12699.1|ARO:3005091|RanA	34.2	225	313	258	9.55e-31	115
k141_93050_4	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	27.8	313	313	351	1.81e-24	100
k141_93050_4	SARG|gb|AAR96051.1|ARO:3002894|otrC	27.8	313	313	351	2.50e-24	100
k141_93050_4	SARG|gb|AAK76137.1|ARO:3000024|patA	26.5	211	313	564	1.28e-14	73.2
k141_127737_1	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	39.3	196	229	655	8.32e-40	143
k141_127737_1	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	39.3	196	229	655	8.32e-40	143
k141_127737_1	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	39.3	196	229	655	8.32e-40	143
k141_127737_1	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	39.3	196	229	655	8.32e-40	143
k141_127737_1	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	39.3	196	229	655	8.32e-40	143
k141_127737_1	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	39.3	196	229	655	8.32e-40	143
k141_127737_1	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	39.3	196	229	655	8.32e-40	143
k141_127737_1	SARG|gb|AKA86814|ARO:3003746|optrA	39.3	196	229	655	8.32e-40	143
k141_127737_1	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.8	196	229	655	5.62e-39	141
k141_127737_1	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.8	196	229	655	5.62e-39	141
k141_44599_9	SARG|Q04720	32.6	193	256	287	1.04e-23	95.9
k141_44599_9	SARG|M29832.gene.p01	32.6	193	256	287	1.04e-23	95.9
k141_44599_9	SARG|P45438	32.6	193	256	287	1.45e-23	95.5
k141_44599_9	SARG|AY234334.1.orf0.gene.p01	30.8	214	256	281	3.49e-22	91.7
k141_44599_9	SARG|gb|CZT31773.1|ARO:3004094|Erm(48)	30.0	217	256	243	3.38e-18	80.1
k141_44599_9	SARG|L22689.1.gene1.p01	29.7	239	256	257	1.11e-17	79.0
k141_44599_9	SARG|BBJ25230.1	31.5	197	256	263	1.85e-14	70.1
k141_44599_9	SARG|gb|OPG86592.1|ARO:3004626|Erm(49)	30.2	202	256	304	2.39e-13	67.4
k141_44599_9	SARG|gb|CBY77552.1|ARO:3003106|Erm(42)	31.6	171	256	301	3.19e-13	67.0
k141_44599_9	NCBI|WP_052259183.1|1|1|erm(42)|erm(42)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN|LINCOSAMIDE/MACROLIDE|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(42)|AMR|multidrug	31.6	171	256	301	3.19e-13	67.0
k141_135341_7	SARG|gi|746243059|ref|WP_039291473.1|	43.2	222	235	648	5.49e-53	179
k141_135341_7	SARG|gi|495736522|ref|WP_008461101.1|	42.3	222	235	648	2.83e-51	175
k141_135341_7	SARG|gi|746253210|ref|WP_039301529.1|	42.3	222	235	648	2.83e-51	175
k141_135341_7	SARG|gi|1001720867|ref|WP_061274204.1|	41.9	222	235	648	7.58e-51	174
k141_135341_7	SARG|gi|921979807|ref|WP_053271336.1|	41.4	222	235	648	1.05e-50	173
k141_135341_7	SARG|gi|923061916|ref|WP_053445667.1|	41.0	222	235	648	7.51e-50	171
k141_135341_7	SARG|gi|895865878|ref|WP_048974758.1|	39.2	222	235	646	6.75e-46	160
k141_135341_7	SARG|gb|AYV52072.1|ARO:3002882|lmrD	27.8	205	235	664	1.53e-17	80.1
k141_135341_7	SARG|gb|AAK76137.1|ARO:3000024|patA	30.2	205	235	564	4.86e-17	78.6
k141_135341_7	SARG|gb|AAK76136.1|ARO:3000025|patB	28.3	205	235	588	9.06e-17	77.8
k141_135341_8	SARG|gi|639225329|ref|WP_024561799.1|	37.1	318	878	648	2.41e-52	193
k141_135341_8	SARG|gi|647323678|ref|WP_025760497.1|	36.5	340	878	648	2.41e-52	193
k141_135341_8	SARG|gi|639218559|ref|WP_024556062.1|	37.1	318	878	648	2.41e-52	193
k141_135341_8	SARG|Q83LR7	36.5	340	878	648	4.44e-52	192
k141_135341_8	SARG|gi|647325472|ref|WP_025760953.1|	36.5	340	878	648	4.44e-52	192
k141_135341_8	SARG|gi|754927849|ref|WP_042284850.1|	34.8	342	878	648	8.16e-52	191
k141_135341_8	SARG|gi|446110305|ref|WP_000188160.1|	36.2	340	878	648	1.50e-51	191
k141_135341_8	SARG|gi|657888313|ref|WP_029592374.1|	36.0	314	878	648	3.72e-51	189
k141_135341_8	SARG|gi|736472622|ref|WP_034494292.1|	36.0	314	878	648	5.04e-51	189
k141_135341_8	SARG|gi|654544841|ref|WP_028012549.1|	36.5	315	878	646	6.64e-51	189
k141_58564_1	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	57.3	225	225	255	1.65e-86	255
k141_58564_1	SARG|gb|AAV85982.1|ARO:3000535|macB	39.0	223	225	644	5.06e-49	168
k141_58564_1	SARG|gi|896325272|ref|WP_049294291.1|	40.1	222	225	648	7.18e-48	165
k141_58564_1	SARG|gi|639216333|ref|WP_024554080.1|	40.1	222	225	648	1.38e-47	164
k141_58564_1	SARG|gi|639225329|ref|WP_024561799.1|	40.1	222	225	648	3.66e-47	163
k141_58564_1	SARG|YP_001571041	38.8	224	225	648	3.66e-47	163
k141_58564_1	SARG|gi|639218559|ref|WP_024556062.1|	40.1	222	225	648	3.66e-47	163
k141_58564_1	SARG|gi|960873409|ref|WP_058345546.1|	38.8	224	225	648	3.66e-47	163
k141_58564_1	SARG|gi|657888313|ref|WP_029592374.1|	40.1	222	225	648	5.07e-47	163
k141_58564_1	SARG|gi|740610794|ref|WP_038396317.1|	38.4	224	225	648	1.34e-46	162
k141_58564_2	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	32.4	336	340	341	1.65e-49	167
k141_58564_3	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	39.7	219	221	223	7.78e-48	155
k141_58564_3	CARD|gb|AAD51348.1|ARO:3003066|smeR	32.5	203	221	229	1.63e-32	116
k141_58564_3	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	29.5	227	221	232	1.36e-31	114
k141_58564_3	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	29.5	227	221	232	1.36e-31	114
k141_58564_3	CARD|gb|ADM92605.1|ARO:3000553|adeR	29.6	226	221	247	8.12e-30	110
k141_58564_3	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	29.7	209	221	231	1.11e-29	109
k141_58564_3	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	30.7	225	221	231	1.56e-29	108
k141_58564_3	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	28.9	232	221	235	2.41e-29	108
k141_58564_3	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	29.3	225	221	231	6.08e-29	107
k141_58564_3	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	30.4	230	221	233	1.25e-28	106
k141_37413_4	NCBI|WP_063856871.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.2	265	329	346	1.28e-25	103
k141_37413_4	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	29.8	265	329	356	2.78e-25	103
k141_37413_4	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.8	266	329	356	3.83e-25	102
k141_37413_4	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.8	266	329	356	5.28e-25	102
k141_37413_4	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.1	256	329	355	9.86e-25	101
k141_37413_4	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	30.1	256	329	355	9.86e-25	101
k141_37413_4	SARG|ACM47285	30.1	256	329	363	1.09e-24	101
k141_37413_4	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	28.7	265	329	355	9.16e-24	99.0
k141_37413_4	SARG|BAE96115	28.7	265	329	355	9.16e-24	99.0
k141_37413_4	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	29.4	214	329	209	3.82e-17	77.8
k141_97235_2	CARD|gb|CAA79966.1|ARO:3003665|NmcR	30.2	139	293	295	1.03e-07	51.2
k141_97235_4	SARG|gi|505177635|ref|WP_015364737.1|	20.0	441	468	451	6.43e-12	66.2
k141_97235_4	SARG|ZP_04679156	19.7	441	468	451	6.20e-11	63.2
k141_97235_4	SARG|YP_302230	22.7	229	468	451	5.94e-10	60.1
k141_117915_2	SARG|gi|740856590|ref|WP_038641842.1|	28.0	236	266	648	2.95e-17	80.1
k141_117915_2	SARG|gi|851928815|ref|WP_048221086.1|	25.8	279	266	648	9.81e-17	78.6
k141_117915_2	SARG|gi|780033092|ref|WP_045444768.1|	25.8	279	266	648	9.81e-17	78.6
k141_117915_2	SARG|gi|851913025|ref|WP_048215946.1|	27.7	224	266	648	1.32e-16	78.2
k141_117915_2	SARG|gi|489930965|ref|WP_003834285.1|	27.7	224	266	648	1.32e-16	78.2
k141_117915_2	SARG|gi|696368937|ref|WP_032943949.1|	27.7	224	266	648	1.79e-16	77.8
k141_117915_2	SARG|gi|922960663|ref|WP_053388845.1|	28.4	225	266	648	1.79e-16	77.8
k141_117915_2	SARG|YP_002850060	27.7	224	266	648	2.41e-16	77.4
k141_117915_2	SARG|gi|757799695|ref|WP_043016897.1|	27.8	227	266	648	4.39e-16	76.6
k141_117915_2	SARG|gi|1045891604|ref|WP_065554100.1|	27.8	227	266	648	4.39e-16	76.6
k141_82861_1	NCBI|CCA59315.1|1|1|helR|helR||1|rifamycin|rifamycin|RNA_polymerase_recycling_motor_ATPase_HelR|AMR|rifamycin	44.0	84	509	722	6.41e-12	67.0
k141_34525_2	SARG|ACF08831	34.6	153	396	639	2.55e-16	79.7
k141_34525_2	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	37.6	133	396	639	6.05e-16	78.6
k141_72039_1	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	46.2	704	726	1162	2.75e-187	563
k141_72039_1	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	43.3	684	726	1186	1.77e-171	522
k141_72039_1	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	43.3	684	726	1186	1.77e-171	522
k141_72254_2	SARG|ABV82118	23.7	439	605	639	1.02e-24	107
k141_72254_2	SARG|gi|1004359922|gb|AMP42228.1|	26.4	435	605	639	1.36e-24	107
k141_72254_2	megares|MEG_7166|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	24.5	444	605	639	1.36e-24	107
k141_72254_2	SARG|ZP_03989103	23.5	439	605	639	1.80e-24	107
k141_72254_2	SARG|ABV82120	23.5	439	605	639	1.80e-24	107
k141_72254_2	SARG|gi|168258996|gb|ACA23181.1|	25.2	512	605	639	2.39e-24	106
k141_72254_2	SARG|ACA23195	25.2	512	605	639	2.39e-24	106
k141_72254_2	SARG|AJ295238.gene.p01	23.7	439	605	639	4.23e-24	105
k141_72254_2	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.9	436	605	629	5.46e-24	105
k141_72254_2	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.9	436	605	629	5.46e-24	105
k141_100437_3	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	31.8	211	220	341	3.76e-35	126
k141_10185_3	SARG|gb|AGN74946|ARO:3003749|salA	25.6	215	214	541	4.53e-11	60.5
k141_10185_3	SARG|gi|895818174|ref|WP_048942695.1|	27.6	221	214	498	1.47e-10	58.9
k141_10185_3	SARG|gi|488297611|ref|WP_002368819.1|	27.4	215	214	498	1.98e-10	58.5
k141_10185_3	SARG|ZP_04646474	29.4	187	214	498	1.98e-10	58.5
k141_10185_3	SARG|gi|727023243|ref|WP_033594420.1|	27.4	215	214	498	2.68e-10	58.2
k141_10185_3	SARG|gi|895819918|ref|WP_048943810.1|	27.1	221	214	498	2.68e-10	58.2
k141_10185_3	SARG|gi|727017227|ref|WP_033592736.1|	27.4	215	214	498	2.68e-10	58.2
k141_10185_3	SARG|gi|488349878|ref|WP_002419263.1|	27.4	215	214	498	2.68e-10	58.2
k141_10185_3	SARG|gi|881017353|ref|WP_048737885.1|	27.4	215	214	498	2.68e-10	58.2
k141_10185_3	SARG|gi|895828321|ref|WP_048949453.1|	27.4	215	214	498	2.68e-10	58.2
k141_75938_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	29.7	128	271	228	4.27e-12	63.2
k141_75938_2	CARD|gb|ADM92605.1|ARO:3000553|adeR	27.8	126	271	247	4.45e-09	54.7
k141_75938_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	27.4	95	271	219	8.60e-09	53.5
k141_75938_2	CARD|gb|BAB36671.1|ARO:3000832|evgA	26.7	120	271	204	1.83e-08	52.4
k141_90327_1	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	39.7	224	235	225	6.28e-54	172
k141_90327_1	CARD|gb|AAC73788.1|ARO:3003841|kdpE	39.7	224	235	225	6.28e-54	172
k141_90327_1	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	33.1	236	235	239	5.32e-41	139
k141_90327_1	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	36.0	228	235	232	1.74e-40	137
k141_90327_1	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.2	228	235	219	3.44e-40	136
k141_90327_1	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.2	228	235	220	3.54e-40	136
k141_90327_1	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	33.0	224	235	230	9.23e-40	135
k141_90327_1	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.8	228	235	220	1.40e-39	135
k141_90327_1	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	31.1	225	235	229	1.79e-39	135
k141_90327_1	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.8	228	235	220	1.98e-39	134
k141_90327_2	CARD|gb|CYF42523.1|ARO:3004047|kdpD	30.0	250	354	885	1.64e-27	112
